<p><a href="http://us.rd.yahoo.com/dailynews/rss/business/*http://news.yahoo.com/s/nm/20051102/bs_nm/johnsonjohnson_guidant_dc"><img src="http://us.news3.yimg.com/us.i2.yimg.com/p/nm/20051102/2005_11_02t104742_450x327_us_johnsonjohnson_guidan t.jpg?x=130&y=94&sig=kWXf2RMK86jQnKPZ0V3I7 A--" align="left" height="94" width="130" alt="Ronald Dollens, President and Chief Executive Officer of Guidant Corp. is seen at the Reuters Health Summit in New York, November 20, 2003. Johnson and Johnson on Wednesday said it may not complete its $25.4 billion purchase of Guidant, saying the recall of products at the medical device maker had hurt the value of the company. (Mike Segar/Reuters)" border="0" /></a>Reuters - Johnson & Johnson's
planned $25.4 billion purchase of Guidant Corp.
was called into question on Wednesday after the two companies
differed on whether Guidant's long-term financial health had
been irreparably damaged by a recall of its heart devices.</p><br clear=all>
View the entire article:
J&J says may not close Guidant deal (Reuters)
J&J says may not close Guidant deal (Reuters)
Linear Mode
